Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 07:08 am Sale | 2020-12-31 | 13G | Vir Biotechnology, Inc. VIR | Alaska Permanent Fund Corp | 3,893,040 3.060% | -1,662,516 (-29.93%) | Filing History |
| 2021-02-12 5:00 pm Purchase | 2020-12-31 | 13G | Vir Biotechnology, Inc. VIR | SCANGOS GEORGE A | 7,001,308 5.500% | 52,329 (+0.75%) | Filing History |
| 2021-02-11 06:02 am Purchase | 2020-12-31 | 13G | Vir Biotechnology, Inc. VIR | Temasek Holdings (Private) Ltd | 5,499,999 4.300% | 5,499,999 (New Position) | Filing History |
| 2020-07-29 3:50 pm Unchanged | 2020-07-08 | 13D | Vir Biotechnology, Inc. VIR | ARCH Venture Fund IX L.P. | 28,666,663 23.000% | 0 (Unchanged) | Filing History |
| 2020-05-07 07:04 am Unchanged | 2020-04-14 | 13G | Vir Biotechnology, Inc. VIR | Alaska Permanent Fund Corp | 5,555,556 5.060% | 0 (Unchanged) | Filing History |
| 2020-05-04 4:18 pm Purchase | 2020-04-22 | 13G | Vir Biotechnology, Inc. VIR | GSK plc | 6,626,027 6.030% | 6,626,027 (New Position) | Filing History |